Debate contribution: Enhertu
Debate contribution by Mr Robbie Butler on .
- MLA
- Mr Robbie Butler
- Party at the time
- Ulster Unionist Party
- Date
- 21 September 2026
- Type
- Debate contribution
- Business
- Oral Answers to Questions
- Heading
- Enhertu
- Assembly identifier
- Official Report component 5742323
Read the official Assembly record
Text
I thank the Member for his question. Last Thursday was a good news day for many who are suffering. I have been communicating with a number of women who suffer, and I pay tribute to those who wrote on behalf of those who are suffering. We have to remember that, when you have been diagnosed, as many in this Chamber will know, reaching out for help is sometimes not the easiest thing to do. Last Thursday's news was good news. However, we have processes here. Thursday's publication of the updated final draft guidance recommending Enhertu as an option for the treatment of HER2-low metastatic and unresectable breast cancer in adults is great news for patients and families. My Department will formally review the final NICE guidelines once they are published, in line with the normal process. I can confirm that, following the publication of the final draft guidance and in advance of final guidance publication, I will be pleased, and am pleased, to say that Enhertu has been accepted for use in Northern Ireland under the extant HSC-managed entry-of-medicines process. Treatment is commissioned on a cost-per-case basis for individuals who meet the NICE eligibility criteria, and I am sure that I speak for all of us in saying that we all remain active and open to helping those individuals to access that drug as quickly as possible.
227 words. Text as published by the Northern Ireland Assembly.
Assessment
Awaiting analysis
This record has not been analysed yet. It is not counted in any total until it has been assessed.
Disagree with this assessment?
Classifications can be challenged. A person reviews every challenge, and any change is recorded publicly above with its reason.